They are efficacious in treating chemotherapy-induced emesis and postoperative nausea and vomiting. Acute overdosage is often manifested by emesis, lethargy, ataxia, tachycardia and seizures. Acute overdosage is often manifested by emesis, lethargy, ataxia, tachycardia, and seizures. People who might orally ingest acute amounts would experience emesis, diaphoresis, drowsiness and disorientation. Antiemetics are often administered prior to busulfan to prevent vomiting (emesis). Other reported symptoms included nausea, hypotrichosis, chest pain, chest discomfort, emesis, and rash. This case involved seizures manifesting mainly with syncope-like epileptic seizures without emesis. Resistant and severe hiccups, severe nausea/emesis, and preanesthetic conditioning are other uses. In 1955 it was approved in the United States for the treatment of emesis (vomiting). Surgical microvascular decompression resulted in postoperative and long-term resolution of emesis. Chemotherapy-induced emesis appears to consist of acute and delayed phases. T-2328 is administered intravenously, and treats both acute and delayed emesis. Side effects including sedation, restlessness, emesis and anxiety were generally rated mild. Chemotherapy-induced emesis is a major problem in cancer treatment. This blockade of opioid-induced emesis was demonstrated in a canine model.